- Market Research
- Autologous Conditioned Plasma Therapy Market Segmented By Pure Platelet-Rich Plasma (P-PRP), Leukocyte- and Platelet-Rich Plasma (LPRP), Pure Platelet-Rich Fibrin (P-PRF), Leukocyte- and Platelet-Rich Fibrin (L-PRF) Composition with Autologous Platelet-Rich Plasma, Allogeneic Platelet-Rich Plasma, Homologues Platelet-Rich Plasma Sources with Skin Ulcers, Bone Fractures and Grafts, Prostheses Surgeries, Oral Implantology, Sport Injuries & Trauma, Cosmetic Surgeries Indication
Autologous conditioned plasma therapy is used to treat a range of problems, such as musculoskeletal injuries and sports injuries & trauma. Nowadays, it is widely used in treating skin ulcers, sports injuries, and for cosmetic surgeries, besides others. Growing demand for user-friendly therapy procedures is driving the expansion of the autologous conditioned plasma therapy market size.
The procedure provides excellent and effective treatment without the need for undergoing painful surgery. Autologous conditioned plasma therapy is done on an outpatient basis for saving time wasted on hospital stays, and is particularly useful for patients who require both, relief and quick healing. As such, it helps improve patient compliance to the treatment, which is an important factor driving the growth of the global autologous conditioned plasma therapy market, at a high value CAGR of around 12% through 2030.
Find Out More about the Report Coverage
- Zimmer Biomet Inc.
- Terumo Corporation
- DePuy Synthes, Inc. (DePuy Mitek Sports Medicine)
- AdiStem Ltd.
- Arthrex, Inc.
- Stryker Corporation
- Cesca Therapeutics, Inc.
- Biotechnology Institute BTI
- Dr. PRP America LLC
- EmCyte Corporation
- Vivostat A/S
- Regen Lab SA
- Royal Biologics
- Exactech, Inc.
- Plateltex S.R.O.
Autologous Conditioned Plasma Therapy Market Trends
Technological Advancements Aiding Market Expansion: Technological advancements are driving the growth of the autologous conditioned plasma therapy market. For example, on June 11, 2019, EmCyte Corporation announced FDA 510(k) approval for PureBMC® Supraphysiologic Concentrating System for preparing a cell concentrate from bone marrow aspirate and platelet concentrate. This clinical technology optimizes the double spin technique, capturing the essential requirements needed to exceed the clinical requisite for deliverable platelets.
In addition, rising popularity of autologous conditioned plasma fibrin therapy is another factor driving the growth of the autologous conditioned plasma therapy market. It has extensive growth factors and rich platelet content in the form of fibrin membranes, which are free from anti-coagulants or other artificial bio-chemical modifications. P-PRF therapy is known as a second generation platelet concentrate, which promotes rapid and accelerated wound healing.
Progressive Demographic Aging of Older Population to Fuel Market Growth: Aging contributes to soft tissue degeneration and related disorders, particularly of the knee. Autologous conditioned plasma therapy is an effective treatment in knee osteoarthritis management. The elderly account for over one-third of total global hip and shoulder injuries. In the U.S., the most common joint disorder is osteoarthritis. Prevalence of symptomatic knee OA among adults 60 years of age or older is around 13% in women and 10% in men. This factor is likely to drive the global autologous conditioned plasma therapy market over the forecast period of 2020 to 2030.
Rising Incidence of Musculoskeletal Injuries to Propel Demand: The World Health Organization (WHO) states that, musculoskeletal injuries affect millions of people around the world, and is the most common cause of severe long-term pain and physical disability. However, autologous conditioned plasma therapy is an attractive and promising alternative to surgery, for treating musculoskeletal injuries by promoting safe and effective wound healing. As a result of its promising therapeutic potential and excellent regenerative properties, this therapy finds widespread clinical use for musculoskeletal injuries and related diseases. According to a Global Burden of Disease (GBD) study, musculoskeletal disorders and injuries were the highest contributor to global disability, and accounted for 16% of all years lived with disability, and lower back pain remained the single leading cause of disability.
Prevalence of musculoskeletal conditions varies by age and diagnosis; between 20%–33% of people across the globe live with a painful musculoskeletal condition. Rising cases of musculoskeletal injuries is leading to increased demand for autologous conditioned plasma therapy for treating musculoskeletal injuries.
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
COVID-19 Impact on Autologous Conditioned Plasma Therapy Market
As the spread of COVID-19 continues, it is negatively affecting almost all industries, and has also adversely affected the autologous conditioned plasma therapy market. There has been disruptions in the supply-chain due to global restrictions. Local governments and companies are allocating funds for the expansion of existing facilities and construction of new facilities to tackle the COVID-19 pandemic.
As coronavirus has become the main focus, many pharmaceutical and biotech companies are engaged in developing a potent vaccine. This is expected to hamper the clinical development activities of leading autologous conditioned plasma therapy market players during the duration of the COVID-19 pandemic.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
An extensive analysis of the autologous conditioned plasma therapy market has brought our analysts to a conclusion that, the market is growing at a significant pace. Currently, pure platelet-rich fibrin (P-PRF) is a targeted segment for major players in the autologous conditioned plasma therapy market, due to extensive growth factors and rich platelet content in the form of fibrin membranes.
North America and Europe collectively hold more than 70% of autologous conditioned plasma therapy market share as far as revenue is concerned, due to high demand and technological advancements in these regions. Emerging countries such as China and Brazil are expected to offer lucrative opportunities for the growth of the autologous conditioned plasma therapy market, owing to increasing pool of patients and rising awareness among the population.
Explore Persistence Market Research’s expertise in promulgation of the business !
Key Segments of Autologous Conditioned Plasma Therapy Market
PMR’s study on the autologous conditioned plasma therapy market offers information divided into five important segments—composition, source, indication, end user, and region. This report offers comprehensive data and information about the important market dynamics, and growth parameters associated with these categories.